Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL

1. A crystalline polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol characterized by having essentially all of the °2θ values listed in Table 1±0.2°2θ:

TABLE 1

Pos. [°2θ]

d-spacing [Å]

12.1

7.3

14.2

6.2

18.2

4.9

19.2

4.6

20.1

4.4

21.0

4.2

21.9

4.1

22.7

3.9

24.3

3.7

26.6

3.4

27.6

3.2

30.9

2.9

31.5

2.8

34.7

2.6

39.5

 2.3.

2. A crystalline polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol having, upon X-ray crystallographic analysis, crystal parameters of substantially the following values:

Crystallographic system: orthorhombic

Space group: P2 1 2 1 2 1

Crystal dimensions: a=9.1045(2) Å, b=10.3107(2) Å, c=14.5988(3) Å

α=90.00°, β=90.00°, γ=90.00°

Volume 1370.44(5) Å 3

Z, calculated density 4, 1.326 g cm −3 .

3. A crystalline polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol, characterized by having upon Raman spectroscopic analysis, all of the peaks having substantially the wavenumbers (cm −1 ) of 3076.4, 3054.6, 2987.4, 2975.5, 2954.2, 2928.0, 2909.8, 2896.0, 1578.6, 1298.2, 1291.6, 1263.0, 1226.8, 1068.9, and 694.9, ±50 wave numbers.

4. The crystalline polymorph of claim 3 , having a multiplet of peaks between about 2800 and about 3200 cm −1 , ±50 wavenumbers, and another multiplet of peaks between about 1600 and about 600 cm −1 , ±50 wavenumbers, and an essential absence of peaks between about 1800 and about 2200 cm −1 , ±50 wavenumbers.

5. A pharmaceutical composition comprising:

a) the crystalline polymorph of claim 1 ; and

b) at least one excipient or carrier.

6. A method for treating a disease in an animal suffering from a disease, comprising:

administering to the animal a therapeutically effective amount of the crystalline polymorph of claim 1 ,

wherein said disease is associated with a bacteria.

7. The method of claim 6 , wherein the bacteria is a Gram negative bacteria.

8. The method of claim 6 , wherein the bacteria is selected from the group consisting of Neisseria species, Escherichia species, Shigella species, Salmonella species, Yersinia species, Klebsiella species, Proteus species, Enterobacter species, Serratia species, Vibrio species, Campylobacter species, Helicobacter species, Pseudomonas species, Bacteroides species, Haemophilus species, Bordetella species, Legionella species, Francisella species, Brucella species, Pasteurella species, Gardnerella species, Spirochetes species, Chlamydia species and Rickettsiae species.

9. The method of claim 6 , wherein the disease is selected from the group consisting of meningitis, gonorrhea, otitis, otitis extema, folliculitis, diarrhea, urinary tract infections, sepsis, HAP, bacteremia, endocarditis, gastroenteritis, Typhoid fever, supsis, endocarditis, sinusitis, bubonic plague, enteric fever, hospital-acquired infection, skin and skin-structure infection, pneumonia, cholera, chronic gastritis, osteomylitis, burn-wound infections, corneal infections, periodontal disease, aspriation pneumonia, piglottitis, septic arthritis, chancroid, vaginitis, whooping cough, pontiac fever, tularemia, brucellosis, syphilis, Lyme disease, chlamydia, Rocky Mountain spotted fever, typhus, tracheobronchitis, walking pneumonia, urethritis, pyelonenephritis, intra-abdominal infection, febrile neutropenia, pelvic infection, bacteraemia, and septicaemia.

10. The method of claim 6 , wherein the disease is pneumonia.

11. A crystalline polymorph of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.HCl having, upon X-ray crystallographic analysis, essentially all of the following °2θ values, ±0.2°2θ: 7.8, 12.3, 14.0, 20.2, 21.3, 22.4, 23.3, 24.7, 27.6, and 32.1.

12. A crystalline polymorph of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.HCl having, upon X-ray crystallographic analysis, essentially all of the following °2θ values, ±0.2°2θ: 6.2, 8.8, 9.8, 12.4, 13.9, 17.7, 22.3, 23.1, 24.3, 24.8, 26.1, 27.2, 28.0, 30.9, 32.2, and 33.

13. A crystalline polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol, produced by evaporation and/or recrystallization from a solution of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.HCl wherein the concentration of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.HCl is from about 11 mg/mL to about 30 mg/mL.

14. A crystalline polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol, produced by evaporation and/or recrystallization from a solution of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.HCl wherein the concentration of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.HCl is from about 15 mg/mL to about 50 mg/mL.